Join

Compare · NVS vs XLO

NVS vs XLO

Side-by-side comparison of Novartis AG (NVS) and Xilio Therapeutics Inc. (XLO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVS and XLO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $289.20B, about 5273.8x XLO ($54.8M).
  • Over the past year, NVS is up 27.7% and XLO is down 12.0% - NVS leads by 39.7 points.
  • XLO has been more active in the news (10 items in the past 4 weeks vs 1 for NVS).
  • NVS has more recent analyst coverage (25 ratings vs 7 for XLO).
PerformanceNVS+29.51%XLO-12.04%
2025-06-17+0.00%2026-06-16
MetricNVSXLO
Company
Novartis AG
Xilio Therapeutics Inc.
Price
$150.77-0.53%
$8.45+6.29%
Market cap
$289.20B
$54.8M
1M return
+1.81%
-5.53%
1Y return
+27.66%
-12.04%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
1
10
Recent ratings
25
7
NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

XLO

Xilio Therapeutics Inc.

Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Latest NVS

Latest XLO